The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Count Me In, a non-profit research initiative that conducts patient-partnered studies of cancer, were awarded a $16 million grant from NCI to accelerate research in two rare forms of cancer.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
